Could a 14-Day pill reverse stomach precancer?
NCT ID NCT06590454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug pyrvinium can reverse gastric intestinal metaplasia, a condition that raises the risk of stomach cancer. Thirty-two adults with high-risk features will take pyrvinium or a placebo for 14 days. Researchers will compare biopsies before and after treatment to see if the precancerous changes improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pyrvinium
What this could lead to
If it works, this could point toward a drug treatment to reverse precancerous changes in the stomach and lower the risk of stomach cancer.
What could go wrong
This is a small early-phase trial with only 32 people. The drug may not reverse the precancerous changes, and side effects are possible. Success in the lab may not translate to real-world benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC INTESTINAL METAPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke Health
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact